Published in Ter Arkh on January 01, 1986
Novel functional activities of anti-DNA autoantibodies from sera of patients with lymphoproliferative and autoimmune diseases. Appl Biochem Biotechnol (1998) 0.96
Ovarian function and disease activity in patients with systemic lupus erythematosus. Clin Exp Rheumatol (2008) 0.92
[Down-regulation of RBSP3/CTDSPL, NPRL2/G21, RASSF1A, ITGA9, HYAL1 and HYAL2 genes in non-small cell lung cancer]. Mol Biol (Mosk) (2009) 0.87
[Novel reference gene RPN1 for normalization of quantitative data in lung and kidney cancer]. Mol Biol (Mosk) (2011) 0.86
Molecular pathogenesis of systemic lupus erythematosus. Arch Virol (1975) 0.85
Anti-DNA autoantibodies reveal toxicity to tumor cell lines. Immunol Lett (2002) 0.85
[Increase in NETO2 gene expression is a potential molecular genetic marker in renal and lung cancers]. Genetika (2012) 0.84
[Differential expression of genes that encode glycolysis enzymes in kidney and lung cancer in humans]. Genetika (2013) 0.84
[Dynamic changes in synovitis activity after intra-articular administration of xefocam in patients with rheumatoid arthritis (according to clinical and device examinations)]. Ter Arkh (2003) 0.84
DNA-specific antiidiotypic antibodies in the sera of patients with autoimmune diseases. FEBS Lett (1992) 0.83
[Expression of FTL and FTH genes encoding ferretin subunits in lung and renal carcinomas]. Mol Biol (Mosk) (2010) 0.83
Endocarditis with left atrial thrombus formation in Behçet's disease mimicking myxoma. J Rheumatol (1993) 0.82
[Antibodies to various phospholipids in SLE patients with primary antiphospholipid syndrome]. Klin Med (Mosk) (1999) 0.81
[Tumor suppressor gene RBSP3 in cervical carcinoma: copy number and transcriptional level]. Mol Biol (Mosk) (2007) 0.80
[Effect of exogenous interferon and various interferon inducers on the indicators of general reactivity in systemic lupus erythematosus]. Ter Arkh (1980) 0.79
[Madecassol treatment of systemic and localized scleroderma]. Ter Arkh (1998) 0.79
[Characteristics of retinal vascular involvement in systemic lupus erythematosus]. Vestn Oftalmol (2001) 0.78
[The HLA-B5 immunogenetic marker in Behçet's disease]. Ter Arkh (1993) 0.78
[Clinical significance of determining antibodies to poly A: poly U in systemic lupus erythematosus]. Ter Arkh (1972) 0.78
[Catalytic autoantibodies--a new molecular instrument in cardiology and ophthalmology]. Ter Arkh (2006) 0.78
[Atherogenic cholesterol-containing circulating immune complexes--one of the components of the serum in patients with systemic lupus erythematosus]. Klin Med (Mosk) (2003) 0.78
[Cardiovascular diseases in rheumatoid arthritis]. Ter Arkh (2007) 0.77
[Role of antiphospholipid antibodies in occlusion of retinal vessels in various vascular eye diseases]. Vestn Oftalmol (2002) 0.77
[Clinical implication of assessment of heart rate variability in patients with psoriatic arthritis]. Ter Arkh (2009) 0.77
[Evaluation of Gene Expression of Hexokinases in Colorectal Cancer with the Use of Bioinformatics Methods]. Biofizika (2016) 0.77
[Behçet's disease: clinical and demographic associations]. Ter Arkh (2013) 0.77
[Cardiological aspects of the antiphospholipid syndrome. Part I. Valvular lesions in the primary and secondary antiphospholipid syndrome and systemic lupus erythematosus]. Kardiologiia (2002) 0.77
[The local therapy of enthesitis and bursitis of the calcaneal area in seronegative spondylarthritis]. Ter Arkh (1997) 0.76
[Subclinical and clinical manifestations of atherosclerosis in antiphospholipid syndrome]. Ter Arkh (2008) 0.76
[Soluble CD40 ligand in systemic lupus erythematosus and antiphospholipid syndrome]. Ter Arkh (2006) 0.76
[DNA-abzymes in rheumatoid arthritis: pathogenetic and clinical significance]. Ter Arkh (2005) 0.76
[Immunopathologic study of the myocardium in dilated cardiomyopathy]. Arkh Patol (1992) 0.76
[Genetic diversity and evolution of the influenza C virus]. Genetika (2012) 0.76
[Antibodies to beta2-glycoprotein I in systemic lupus erythematosus: new laboratory marker of antiphospholipid syndrome]. Klin Med (Mosk) (1998) 0.76
[The role of estrogen-androgen imbalance in rheumatic diseases]. Ter Arkh (1990) 0.76
Endothelial inclusions and "nuclear bodies" in systemic lupus erythematosus. Ann Rheum Dis (1973) 0.75
[Dermatomyositis associated with psoriasis]. Ter Arkh (1980) 0.75
[Cryoglobulinemia in Sjögren's syndrome]. Ter Arkh (1990) 0.75
[Mutation of a 5,10-methylenetetrahydrofolate reductase gene in systemic lupus erythematosis and antiphospholipid syndrome]. Ter Arkh (2002) 0.75
[Antibodies to viral antigens in the disorders of the connective tissue]. Sov Med (1973) 0.75
[Simplified method of simultaneous determination of the resorption rate of 2 radioindicators taken from the tissue]. Vopr Revm (1972) 0.75
[Comparative clinico-immunologic and microcirculation studies in families of patients with type 1 diabetes mellitus and systemic lupus erythematosus]. Vestn Akad Med Nauk SSSR (1989) 0.75
[Antiviral immunity in families of patients with systemic lupus erythematosus and in medical personnel in contact with sick patients]. Ter Arkh (1978) 0.75
[Intra-articular application of radioactive gold in infectious nonspecific polyarthritis]. Vopr Revm (1974) 0.75
[Electron-microscopic examination of the skin in systemic lupus erythematosus]. Vestn Dermatol Venerol (1978) 0.75
[Articular lesions in Ixodes tick-borne borreliosis (Lyme disease)]. Vestn Ross Akad Med Nauk (2003) 0.75
Plasma perfusion in treatment of cold rash and systemic lupus erythematosus. Lancet (1979) 0.75
[Differential diagnosis of diffuse eosinophilic fasciitis]. Revmatologiia (Mosk) (1990) 0.75
[Corinfar in the treatment of Raynaud's syndrome in systemic scleroderma (preliminary results)]. Ter Arkh (1985) 0.75
[Primary antiphospholipid syndrome in combination with heterozygous mutation in prothrombin (G20210A) gene: a case report]. Klin Med (Mosk) (2002) 0.75
[Virologic studies in systemic lupus erythematosus]. Vestn Akad Med Nauk SSSR (1977) 0.75
[Leukocyte culture in the study of etiology of systemic lupus erythematosus (SLE)]. Sov Med (1975) 0.75
[Antibodies to viral antigens in rheumatoid arthritis]. Sov Med (1976) 0.75
[Dimethylsulfoxide as a vehicle for vasoactive drugs in the treatment of systemic scleroderma]. Ter Arkh (1982) 0.75
[Sclerodermic pneumofibrosis (clinical-functional characteristics)]. Ter Arkh (1969) 0.75
[Current aspects of the viral etiology of systemic lupus erythematosus]. Vestn Akad Med Nauk SSSR (1975) 0.75
[Current data on the etiology of systemic lupus erythematosus]. Klin Med (Mosk) (1972) 0.75
[Use of dimethylsulfoxide in complex therapy of patients with systemic scleroderma]. Ter Arkh (1977) 0.75
[Extracorporeal therapy (hemosorption, plasmapheresis) in the combined treatment of severe forms of Sjögren's disease]. Vutr Boles (1988) 0.75
[Soluble receptors of TNF-alpha: association with atherosclerotic vascular affection in systemic lupus erythematosus in males]. Ter Arkh (2006) 0.75
[Survival and prognostic factors of death risk in antiphospholipid syndrome: results of 8-year follow-up]. Ter Arkh (2003) 0.75
[Dynamic studies of skin microcirculation during treatment of lupus nephritis with cytostatic immunosuppressants]. Ter Arkh (1980) 0.75
[The significance of cardiovascular risk factors and C-reactive protein to the development of atherosclerosis in women with systemic lupus erythematosus]. Klin Med (Mosk) (2006) 0.75
[Muscular pathology in rheumatoid arthritis: a clinico-morphological study]. Klin Med (Mosk) (1996) 0.75
[Interferon reaction of leukocytes in diffuse connective tissue diseases]. Sov Med (1976) 0.75
[The role of suprasegmental and segmental autonomic disorders in the development of muscular syndrome of rheumatoid arthritis]. Ter Arkh (2002) 0.75
[Current studies on etiology of rheumatoid arthritis and related diseases]. Ter Arkh (1977) 0.75
[Anti-measles antibodies in systemic lupus erythematosus]. Sov Med (1972) 0.75
[Effect of vazaprostan on microcirculation in patients with scleroderma systematic]. Ter Arkh (2000) 0.75
[Microcirculatory disorders in the genesis of sclerodermic nephropathy]. Ter Arkh (1986) 0.75
[Antibodies to desoxyribonucleic acid (DNA) in diffuse connective tissue diseases]. Ter Arkh (1972) 0.75
[Thrombo ASS in the prophylaxis of vascular disorders in antiphospholipid syndrome]. Klin Med (Mosk) (1999) 0.75
[Effect of hyperbaric oxygenation on the microcirculatory state in clinically manifest rheumatoid vasculitis]. Ter Arkh (1982) 0.75
[Vascular symptoms of Behcet's disease]. Ter Arkh (2005) 0.75
[Isolation of antibodies to native DNA in patients with systemic lupus erythematosus by the method of adsorption on nitrocellulose filters]. Ter Arkh (1974) 0.75
[Treatment of Raynaud's syndrome with calcium entry blockers]. Ter Arkh (1987) 0.75
[Microcirculatory disorders in vasculitis of the skin]. Vestn Dermatol Venerol (1984) 0.75
[Use of laser Doppler flowmetry in various rheumatic diseases]. Revmatologiia (Mosk) (1988) 0.75
[Assessment of tissue microcirculation in patients with aseptic necrosis of femur heads in systemic lupus erythematosus (SLE)]. Ter Arkh (1999) 0.75
[Rate of absorption of Na24Cl and I-131-hippuran from the intramuscular depot]. Med Radiol (Mosk) (1970) 0.75
[Yersinia enterocolitica and rheumatic diseases (a review of the literature)]. Vopr Revm (1979) 0.75
[The vasoprostan treatment of patients with Raynaud's syndrome]. Ter Arkh (1997) 0.75
[Systemic sclerosis with a rapidly progressing course]. Ter Arkh (1981) 0.75
[Value of determination of skin microcirculation in systemic lupus erythematosus]. Ter Arkh (1979) 0.75
[Atheroscleotic vascular lesion in systemic lupus erythematosus and antiphospholipid syndrome in men]. Klin Med (Mosk) (2006) 0.75
[Microcirculatory disorders in systemic scleroderma treated with d-penicillamine]. Klin Med (Mosk) (1981) 0.75
[Tubuloreticular structures in the peripheral blood elements in systemic lupus erythematosus]. Ter Arkh (1977) 0.75
[Antibodies to double-helical RNA and several viruses in medical personnel caring for systemic lupus erythematosus patients]. Vopr Virusol (1979) 0.75
[Antiphospholipid syndrome and exogenic risk factors in thromboses]. Ter Arkh (2004) 0.75
[The condition of peripheral arteries in patients with systemic lupus erythematosus]. Klin Med (Mosk) (2004) 0.75
[Comparative evaluation of tissue microcirculation in patients with aseptic necrosis of the femur head in rheumatoid arthritis and systemic lupus erythematosus]. Ter Arkh (2001) 0.75
[Status of tissue microcirculation in psoriatic arthritis]. Ter Arkh (1986) 0.75
[Methods for the instrumental diagnosis and verification of Lyme arthritis]. Ter Arkh (1997) 0.75
[Comparative evaluation of the treatment of Sjögren's syndrome with anti-rheumatic preparations]. Ter Arkh (1988) 0.75
[Prevalence of antibodies to double-stranded RNA in medical personnel having contact with patients with systemic lupus erythematosus]. Ter Arkh (1977) 0.75
[Antibodies to double-stranded RNA, ribosomal RNA and single-stranded DNA in the blood serum of healthy and sick persons of different ages]. Vopr Med Khim (1973) 0.75
[Atherosclerotic lesion of the vessels in systemic lupus erythematosus in males: relations with concentration of C-reactive protein]. Ter Arkh (2005) 0.75
[Corticosteroids in the treatment of secondary antiphospholipid syndrome]. Klin Med (Mosk) (2002) 0.75